Last Updated: June 27, 2026

Suppliers and packagers for romvimza


✉ Email this page to a colleague

« Back to Dashboard


romvimza

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304 NDA Deciphera Pharmaceuticals, LLC 73207-302-40 1 CARTON in 1 CARTON (73207-302-40) / 1 BLISTER PACK in 1 CARTON / 8 CAPSULE in 1 BLISTER PACK 2025-02-14
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304 NDA Deciphera Pharmaceuticals, LLC 73207-302-41 1 CARTON in 1 CARTON (73207-302-41) / 1 BLISTER PACK in 1 CARTON / 4 CAPSULE in 1 BLISTER PACK 2025-02-14
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304 NDA Deciphera Pharmaceuticals, LLC 73207-303-40 1 CARTON in 1 CARTON (73207-303-40) / 1 BLISTER PACK in 1 CARTON / 8 CAPSULE in 1 BLISTER PACK 2025-02-14
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304 NDA Deciphera Pharmaceuticals, LLC 73207-303-41 1 CARTON in 1 CARTON (73207-303-41) / 1 BLISTER PACK in 1 CARTON / 4 CAPSULE in 1 BLISTER PACK 2025-02-14
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304 NDA Deciphera Pharmaceuticals, LLC 73207-304-40 1 CARTON in 1 CARTON (73207-304-40) / 1 BLISTER PACK in 1 CARTON / 8 CAPSULE in 1 BLISTER PACK 2025-02-14
Deciphera Pharms ROMVIMZA vimseltinib CAPSULE;ORAL 219304 NDA Deciphera Pharmaceuticals, LLC 73207-304-41 1 CARTON in 1 CARTON (73207-304-41) / 1 BLISTER PACK in 1 CARTON / 4 CAPSULE in 1 BLISTER PACK 2025-02-14
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Subscribe to access the full database, or Start Trial

Suppliers and packagers for romvimza

Last updated: June 1, 2026

Romvimza suppliers (API, drug product, and contract manufacturing): Who makes it and where is it sourced?

No reliable, complete supplier mapping for Romvimza (including API manufacturers, drug product contract manufacturers, and packaging/labeling suppliers) can be produced from the information available in this session.

Who supplies romvimza active pharmaceutical ingredient (API)?

Featured snippet answer: Not determined.

What API vendors are listed for romvimza

  • Not determinable from the information available.

What routes or intermediates are supplier-dependent

  • Not determinable from the information available.

Which CDMOs manufacture romvimza drug product (tablets, capsules, or injections)?

Featured snippet answer: Not determined.

Drug product dosage form dependence

  • Not determinable from the information available.

Sterile vs non-sterile manufacturing exposure

  • Not determinable from the information available.

Who handles romvimza packaging, labeling, and secondary packaging?

Featured snippet answer: Not determined.

Barcoding, serialization, and compliance logistics

  • Not determinable from the information available.

NDC-level packaging fingerprints

  • Not determinable from the information available.

What does the Orange Book list for romvimza manufacturing and ownership?

Featured snippet answer: Not determined.

Orange Book application holders linked to supply chain

  • Not determinable from the information available.

How to map listed applicants to contract manufacturing

  • Not determinable from the information available.

How many supplier sites exist for romvimza across US and non-US markets?

Featured snippet answer: Not determined.

US vs EU manufacturing footprint

  • Not determinable from the information available.

Parallel supply risks for market continuity

  • Not determinable from the information available.

Which companies are suppliers under licensing, co-development, or commercial distribution deals?

Featured snippet answer: Not determined.

Distributor vs manufacturer roles

  • Not determinable from the information available.

Transfer of manufacturing technology

  • Not determinable from the information available.

What patent, exclusivity, or litigation issues affect romvimza supplier availability?

Featured snippet answer: Not determined.

Manufacturing constraints from formulation or process IP

  • Not determinable from the information available.

Generic or biosimilar supplier entry risks

  • Not determinable from the information available.

Key Takeaways

  • Supplier identification for Romvimza (API, CDMO drug product, and packaging) cannot be completed from the information available in this session.

FAQs

  1. Who are the romvimza API manufacturers?
    Not determined.

  2. What CDMOs manufacture romvimza drug product?
    Not determined.

  3. Who packages and labels romvimza (NDC-specific)?
    Not determined.

  4. Does romvimza have multiple manufacturing sites?
    Not determined.

  5. Do romvimza patents or exclusivity restrict supplier sourcing?
    Not determined.

References

No sources were provided or identifiable in this session to cite.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links